FDA发布API检查指南及PAI新规，8月10日生效

Active Pharmaceutical Ingredient (API) quality is the core foundation of full-life cycle drug safety and the key verification focus of FDA overseas factory inspections and pre-approval inspections (PAI). In September 2025 and August 2026, FDA successively issued two core regulatory documents: PROGRAM 7356.002F API Inspection Guide and the new version of Pre-Approval GMP Inspection (PAI) Guide, which comprehensively upgraded the API production CGMP regulatory system, innovated inspection modes, tightened compliance requirements, and clarified penalty standards.
原料药（API）质量是药品全生命周期安全的核心根基，也是FDA海外工厂检查、上市前审批（PAI）的核心核查重点。2025年9月、2026年8月FDA先后落地两大核心监管文件：PROGRAM 7356.002F《API检查指南》与新版《上市前GMP检查（PAI）指南》，全面升级API生产CGMP监管体系，革新检查模式、收紧合规要求、明确处罚标准。
This article systematically integrates the core contents of the two new regulations, disassembles the underlying logic of FDA API supervision, inspection system, key verification points, latest reforms and violation penalty details, providing a comprehensive compliance guideline for pharmaceutical enterprises in API production, US export, registration application and inspection preparation.

本文将系统性整合两大新规核心内容，拆解FDA API监管底层逻辑、检查体系、核心核查要点、最新变革及违规处罚细则，为药企API生产、出口美国、申报注册、迎检工作提供全方位合规指引。

1. Overview of New Regulations: Comprehensive Upgrade of Risk-Driven & Systematic Supervision｜一、新规整体概述：风险驱动、体系化监管全面升级
   English: The two newly updated FDA core guides continue and strengthen the risk-based systematic inspection strategy, completely abandoning the traditional single-point verification mode. They take the "controlled state of enterprise quality system" as the core judgment standard, covering the entire production life cycle of APIs. Meanwhile, multiple disruptive new rules have been added, including remote supervision replacing on-site inspections, incorporation of ICH Q12 Established Conditions (EC) into core PAI verification, zero tolerance for data integrity violations, and optimization of process validation requirements, which have significantly raised the access threshold for APIs in the US market.
   本次FDA更新的两大核心指南，延续并强化了基于风险的系统化检查策略，彻底摒弃传统单点核查模式，以“企业质量体系受控状态”为核心判定标准，覆盖API全生产生命周期。同时新增多项颠覆性规则：远程监管替代现场检查、ICH Q12既定条件（EC）纳入PAI核心核查、数据完整性一票否决、工艺验证要求优化等，大幅提升美国市场API准入门槛。
   Effective dates of the two core documents:
   两大文件生效时间：

• September 2, 2025: FDA 7356.002F API Inspection Guide officially takes effect, unifying CGMP inspection standards for global API manufacturing plants
• 2025年9月2日：FDA 7356.002F《API检查指南》正式实施，统一全球API工厂CGMP检查标准
• August 10, 2026: New version of PAI Pre-Approval GMP Inspection Guide takes effect, fully updating pre-approval verification rules and enterprise rights and obligations
• 2026年8月10日：新版PAI《上市前GMP检查指南》生效，全面更新上市前核查规则与企业权责

2. Underlying Supervision Basis: Regulatory Framework & Core Guidance System｜

2. 监管底层依据：法规框架与核心指导体系
   FDA’s supervision of APIs is not based on a single standard, but a three-dimensional system with statutory regulations as the bottom line, ICH guidelines as practical operation criteria, and diversified supervision tools as supplements.
   FDA对API的监管并非单一标准，而是以法定法规为底线、ICH指南为实操准则、多元监管工具为补充的立体化体系。
   
   
   2.1 Mandatory Statutory Core Regulations｜2.1 法定核心法规（强制执行）
   Rooted in the US Federal Food, Drug, and Cosmetic Act (FD&C Act), the core clauses are as follows:
   以美国《联邦食品、药品和化妆品法案》（FD&C Act）为根本依据，核心条款包括：

• Section 501(a)(2)(B): Clarifies that all API production must comply with Current Good Manufacturing Practice (CGMP), serving as the core legal basis for FDA to judge whether APIs are adulterated or non-compliant
• 第501(a)(2)(B)条：明确所有API生产必须符合CGMP现行良好生产规范，是FDA判定API是否掺假、不合规的核心法律依据
• Section 510: Mandates domestic and foreign API manufacturers to complete facility registration and listed product listing; unregistered and unlisted products are prohibited from entering the US market
• 第510条：强制要求国内外API生产企业完成机构注册、在售API产品列名，未注册列名产品禁止进入美国市场
  Key Note: The FD&C Act makes no distinction between APIs and finished dosage forms, with equally strict CGMP compliance requirements for both. API quality defects can directly result in drug disqualification.
  重点说明：FD&C法案不区分API与成品制剂，二者CGMP合规要求同等严格，API质量缺陷可直接判定药品不合格。
  
  
  2.2 Core ICH Guidance Guidelines (Exclusive Practical Standards)｜2.2 核心ICH指导指南（实操唯一标准）
  English: Four ICH guidelines form the practical framework for API inspections, covering the entire process of production, quality, risk and life cycle management:
  四大ICH指南构成API检查实操框架，贯穿生产、质量、风险、生命周期全流程：
• ICH Q7 (2001): Core CGMP guideline for API production and the basic framework for all on-site inspections
• ICH Q7（2001）：API生产CGMP核心指南，所有现场检查的基础框架
• ICH Q9(R1) (2023 Latest Version): Principle of full-life cycle quality risk management, the core basis for risk-based graded inspections
• ICH Q9(R1)（2023最新版）：全生命周期质量风险管理原则，是风险分级检查的核心依据
• ICH Q10 (2009): Pharmaceutical quality system construction standards, regulating the whole process of enterprise quality control
• ICH Q10（2009）：药品质量体系搭建标准，规范企业质量管控全流程
• English: ICH Q12 (2021): Drug life cycle management rules, the key newly added verification content of the 2026 revised PAI
• ICH Q12（2021）：药品生命周期管理规则，2026新版PAI重点新增核查内容
  
  
  2.3 Diversified Supervision Tools
  多元化监管工具
  English: FDA is no longer limited to traditional on-site inspections, and can conduct comprehensive evaluation through multi-dimensional information, including past inspection records, overseas regulatory cooperation reports, and Remote Regulatory Assessment (RRA) (remote document review, online interactive verification), realizing full-coverage and dead-angle-free supervision.
  中文：FDA不再局限于传统现场检查，可结合多维度信息开展综合评估：FDA过往检查记录、海外合作监管机构报告、远程监管评估（RRA）（远程调阅记录、线上互动核查）等，实现全方位无死角监管。

3. Supervision Coverage: Verified & Exempted API Categories｜三、监管覆盖范围：明确核查与豁免API品类
   English: The new regulations clearly define the boundaries of API supervision and accurately divide covered and exempted categories to avoid enterprise compliance deviations.
   中文：新规清晰界定了API监管边界，精准划分覆盖品类与豁免品类，避免企业合规偏差。
   
   
   3.1 Fully Verified Categories
   全覆盖核查品类

• Chemically synthesized small-molecule APIs and key production intermediates
  化学合成类小分子API及生产关键中间体
• Polypeptide APIs with ≤40 amino acids produced by chemical synthesis or fermentation processes
  化学合成/发酵工艺生产的≤40个氨基酸多肽类API
• Antibiotics and other small-molecule APIs produced by microbial fermentation
  微生物发酵生产的抗生素及其他小分子API
  
  
  3.2 Clearly Exempted Categories (Regulated Under Biological Products System)
  明确豁免品类（归属于生物制品监管体系）
  The following biological APIs are not regulated by this guideline, but exclusively supervised by FDA’s Center for Biologics Evaluation and Research (CBER): blood products, vaccines, allergens, tissue, cell and gene therapy APIs.
  以下生物类API不由本指南监管，由FDA生物制品评价与研究中心（CBER）专属监管：血液制品、疫苗、变应原、组织、细胞及基因治疗类API。
  
  
  3.3 Special Scenario Instructions
  特殊场景说明
  English: For sterile APIs, only the entire production process before sterilization is supervised; sterilization and aseptic filling links follow exclusive sterile inspection specifications. Bulk finished drugs that are repackaged only with consistent API production processes are included in the scope of this guideline’s supervision.
  无菌API仅监管灭菌前全生产流程，灭菌、无菌灌装环节遵循专属无菌检查规范；与API生产工艺一致、仅完成重新包装的散装成品药，纳入本指南监管范围。

4. Core Professional Definitions (Unified Industry Standards)
   核心专业定义（行业统一标准）
    The new regulations unify industry terminology definitions to eliminate enterprise cognitive deviations. The key core definitions are as follows:
   新规统一行业术语定义，杜绝企业认知偏差，核心关键定义如下：

• API (Active Pharmaceutical Ingredient): A drug component that provides pharmacological activity or direct physiological effects in disease diagnosis, treatment or prevention, including derivative forms with chemical modification during production but retaining core drug efficacy
• API（活性药物成分）：可在疾病诊疗、预防中提供药理活性或直接生理作用的药物成分，包含生产中发生化学修饰、仍保留核心药效的衍生形式
• API Starting Material: Raw materials or intermediates incorporated into the core molecular structure of APIs, with definite chemical structures and physical and chemical properties, serving as the starting point for API production compliance control
• API起始物料：纳入API核心分子结构的原料/中间体，具备明确化学结构与理化性质，是API生产合规管控的起点
• Intermediate: Materials generated during API production that require further purification or molecular transformation to become finished APIs (only intermediates generated after the enterprise-defined API production starting point are controlled)
• 中间体：API生产过程中生成、需进一步纯化/分子转化方可成为成品API的物料（仅管控企业定义的API生产起始点后生成的中间体）
• Bulk Finished Product: Drug materials with consistent synthesis/fermentationproduction processes as APIs, only repackaged without further deep processing
• 散装成品：生产工艺与API一致，合成/发酵后仅做重新包装、无后续深加工的药物物料

5. FDA Inspection Implementation System: Inspection Types, Teams & Core Framework
   FDA检查实施体系：检查类型、团队与核心框架
   English: FDA adopts a systematic inspection model based on process categories + six core systems, upgrading from single-product verification to overall enterprise quality system assessment, which greatly improves inspection efficiency and accuracy.
   FDA采用基于工艺类别+六大核心系统的系统化检查模式，从单点产品核查升级为企业整体质量体系评估，大幅提升检查效率与精准度。
   
   
   5.1 Two Major Inspection Types
   两大检查类型
   5.1.1 Routine Inspection (Surveillance Inspection)｜5.1.1 监督检查（常规检查）
   English: FDA regular performance inspections for all registered API manufacturers, divided into full inspections and abbreviated inspections.
   FDA常态化履职检查，针对所有在册API生产企业，分为全面检查与简化检查两类。
   English: Full Inspection
   全面检查

•  Applicable scenarios: First verification of newly registered factories, enterprise compliance record fluctuations, major process/facility changes, follow-up inspections after warning letters, and major hidden quality hazard investigation
  适用场景：新注册工厂首次核查、企业合规记录波动、工艺/设施重大变更、警告信后续跟进、重大质量隐患排查
•  Coverage requirements: Verify at least 4 core systems (including the mandatory quality system) to comprehensively evaluate enterprise compliance status
• 覆盖要求：至少核查4大核心系统（必含质量系统），全方位评估企业合规状态
  English: Abbreviated Inspection
  中文：简化检查
•  Applicable scenarios: Enterprises with excellent compliance history, sound risk management systems and no major quality defects for a long time
• 适用场景：企业合规历史优良、风险管理体系完善、长期无重大质量缺陷
•  Coverage requirements: Verify at least 2 core systems (including the mandatory quality system), with rotating verification of other systems to achieve regular supervision
• 覆盖要求：至少核查2大核心系统（必含质量系统），轮换核查其他系统，实现常态化监督
  5.1.2 Targeted Inspection (For-Cause Inspection)
  针对性检查（有因检查）
   Special inspections initiated for specific risk events, including review of previous non-compliance rectification, quality complaints, product recalls, process defects, market adverse reaction traceability, etc., which can be upgraded to full inspections according to risk levels.
  针对特定风险事件启动的专项核查，包括：过往违规整改复核、质量投诉、产品召回、工艺缺陷、市场不良反应等问题溯源核查，可根据风险等级升级为全面检查。
  
  
  5.2 Professional Requirements for Inspection Teams
  检查团队专业要求
  FDA strictly requires inspectors to have corresponding professional qualifications, and may deploy chemists and microbiologists according to inspection needs. Inspectors are proficient in mainstream API production processes such as chemical synthesis and microbial fermentation to accurately identify compliance risks in processes, laboratories and quality systems.
  FDA严格要求检查人员具备对应专业资质，可根据核查需求纳入化学家、微生物学家，熟练掌握化学合成、微生物发酵等主流API生产工艺，精准识别工艺、实验室、质量体系合规风险。
  
  
  5.3 Six Core Verification Systems (Full-Coverage Key Focus)
  六大核心核查系统（全覆盖、重中之重）
  All API inspections must cover the quality system (mandatory), combined with other systems for combined verification. The core verification points of the six systems are as follows:
  所有API检查必须覆盖质量系统（强制必查），搭配其他系统组合核查，六大系统核心核查要点如下：
  5.3.1 Quality System (Core Priority)
  质量系统（核心中的核心）
  The top-level full-process management and control system, the key criterion for judging whether an enterprise is "controlled":
  贯穿全流程的顶层管控体系，是判定企业是否“受控”的关键：
•  Quality department authority: Independent performance mechanism and approval authority for all production, QC and QA procedures
• 质量部门权责：生产、质控、质保所有程序的审核批准权限，独立履职机制
• Data integrity: Synchronous recording of original data, full traceability, no tampering or omission, and complete audit trails
• 数据完整性：原始数据同期记录、全程可追溯、无篡改、无遗漏、审计追踪完整
• Deviation & change management: Scientific traceability of deviation investigations, effective implementation of CAPA, and sufficient risk assessment for all changes
• 变更与偏差管理：偏差调查科学溯源、CAPA纠正预防措施有效落地、所有变更风险评估充分
• Regular management: Annual quality review, full-staff CGMP training, personnel qualification assessment, supplier quality supervision, and complaint & recall handling
• 常态化管控：年度质量审核、全员CGMP培训、人员资质考核、供应商质量监督、召回与投诉处置
  5.3.2 Facility & Equipment System
  设施与设备系统
• Facility layout: Strict zoning control, complete isolation of production areas for high-sensitizing and high-toxic materials to eliminate cross-contamination risks, and reasonable routes for personnel, materials and waste flow
• 设施布局：严格分区管控，高致敏性、高毒性物料生产区域完全隔离，杜绝交叉污染，人流、物流、污物流动线合理
• Equipment management: Non-reactive, non-adsorptive and non-precipitative equipment materials, full-coverage cleaning verification, regular calibration and maintenance with complete records
• 设备管控：设备材质无反应、无吸附、无析出，清洁验证全覆盖，定期校准、维护、记录完整
• Utility systems: Continuous monitoring and compliance verification of key utilities such as steam, compressed air and purified water with no quality risks
• 公用设施：蒸汽、压缩空气、纯化水等关键公用设施持续监控、验证合规，无质量风险
  5.3.3 Material System
  物料系统
• Full-process control: Closed-loop management of identification, quarantine, sampling, testing and release for starting materials, intermediates and packaging materials
  全流程管控：起始物料、中间体、包材的标识、待验、取样、检测、放行全流程闭环管理
• Supply chain control: Supplier audit, dynamic monitoring and effective implementation of quality agreements for key materials
• 供应链管控：关键物料供应商审计、动态监控、质量协议落地
• Warehouse management: Compliant temperature and humidity control, First-In-First-Out (FIFO) principle, and strict control of material validity and re-test periods
• 仓储管理：温湿度合规、先进先出（FIFO）、物料有效期/复验期管控
• Process media: Compliant design and complete verification of process water and process gas systems with continuous controlled status
• 工艺介质：工艺用水、工艺气体系统设计合规、验证完整、持续受控
  5.3.4 Production System
  生产系统
• Process control: Strict implementation of approved production procedures, real-time monitoring of key process parameters, and timely recording, investigation and rectification of major deviations
• 工艺管控：严格执行获批生产规程，关键工艺参数实时监控，重大偏差及时记录、调查整改
•  Process validation: Full-life cycle coverage of process design, confirmation and continuous validation to verify process stability and repeatability
• 工艺验证：覆盖工艺设计、确认、持续验证全生命周期，工艺稳定性、重复性充分验证
•  Quality control: Dynamic yield monitoring, reasonable specifications for intermediates and finished APIs, and controllable impurity risks
• 质量管控：收率动态监控、中间体与API规格科学合理、杂质风险可控
• Solvent control: Recycled solvents can only be used for the same or earlier steps of the identical process with sufficient purification verification and no cross-contamination risks
• 中溶剂管控：回收溶剂仅可用于同工艺相同/更早步骤，纯化验证充分，无交叉污染风险
  5.3.5 Packaging & Labeling System
  包装与贴标签系统
• Label control: Full-process management of label acceptance, storage, issuance and write-off, and partition isolation of similar labels to avoid confusion risks
• 标签管控：标签验收、储存、发放、核销全流程管控，相似标签分区隔离，杜绝混淆风险
• Batch management: Standardized labeling of batch number, validity period and re-test period, and physical isolation during simultaneous packaging and labeling of multiple batches
• 批次管理：批号、有效期、复验期标注规范，多批次同步包装贴标时物理隔离
•  Record integrity: Complete retention of packaging records and label samples for full traceability
• 记录完整性：包装记录、标签样本留存完整，可全程追溯
  5.3.6 Laboratory Control System
  实验室控制系统
•  Method control: Complete verification/confirmation of analytical methods and compliant system suitability of chromatographic, spectroscopic and other detection systems
• 方法管控：分析方法验证/确认完整，色谱、光谱等检测系统适用性达标
• Impurity control: Complete profile of process impurities and degradation impurities with sound impurity traceability and control schemes
• 杂质管控：建立完整工艺杂质、降解杂质谱，杂质溯源与控制方案完善
• Stability study: Complete forced degradation, long-term and accelerated stability tests with true and reliable data
• 稳定性研究：强制降解、长期/加速稳定性试验完整，数据真实可靠
• English: Reference standard control: Clear traceability, compliant qualification and regular review of reference standards
• 标准品管控：参考标准品溯源清晰、资质合规、定期复核

6. Disruptive Reforms of 2026 Revised PAI (Core Industry Focus)
   2026新版PAI颠覆性变革（行业核心重点）
   The 2026 revised PAI guideline is the biggest update to FDA pharmaceutical supervision in recent years, with multiple rules directly changing the logic of pharmaceutical enterprises’ application and inspection preparation. Four core reforms must be prioritized.
   2026年生效的新版PAI指南，是近年FDA药品监管最大更新，多项规则直接改变药企申报与迎检逻辑，四大核心变革必须重点关注。
   
   
   6.1 Remote Regulatory Assessment (RRA) Allowed to Replace On-Site PAI
   远程监管评估（RRA）可替代现场PAI
   English: FDA officially recognizes non-off-site supervision modes. PAI verification can be completed through remote review of enterprise production records, quality documents, test data and online inquiries without on-site inspections. This mode is prioritized for enterprises with excellent compliance records and sound systems, which greatly improves approval efficiency. Meanwhile, it means that enterprises’ daily documents and data compliance can be verified at any time.
   FDA正式认可非现场监管模式，可通过远程调阅企业生产记录、质量文件、检测数据、线上问询等方式，完成PAI核查，无需开展现场检查。该模式优先适用于合规记录优良、体系完善的企业，大幅提升审批效率，同时也意味着企业日常文件、数据合规性随时可被核查。
   
   
   6.2 ICH Q12 Established Conditions (EC) Officially Incorporated into PAI Core Verification
   ICH Q12既定条件（EC）正式纳入PAI核心核查
   English: This is the most critical global CMC reform in this update, marking the official implementation of ICH Q12 life cycle management rules in FDA practical inspections:
   这是本次更新最核心的全球CMC变革，标志着ICH Q12生命周期管理规则正式落地FDA实操检查：

• Audit focus: On-site review of enterprise change management system, verification of whether the declared EC boundaries and change classification (annual report / filing / supplementary application) are supported by sufficient R&D data
• 稽查重点：现场直接审核企业变更管理体系，核对申报的EC边界、变更分级（年度报告/备案/补充申请）是否有充足研发数据支撑
• Undeclared EC disposal: If enterprises fail to clarify EC in applications, FDA will independently determine core EC elements based on risk principles, with no right of defense for enterprises
• 未申报EC处置：若企业申报未明确EC，FDA将依据风险原则自主判定EC核心要素，企业无抗辩权
• Violation consequences: Defective EC system or invalid change management will directly result in FDA 483 observation forms, approval suspension, and may trigger OAI law enforcement and warning letters for marketed products
• 违规后果：EC体系存在漏洞、变更管理失效，直接出具FDA 483缺陷表、暂缓审批，涉及上市产品可触发OAI执法、警告信处罚
  
  
  6.3 Zero-Tolerance Data Integrity with Refined Verification Standards
  数据完整性“一票否决”，细化核查标准
  The revised guideline lists data integrity as a core PAI verification item, clarifying the dual standards of factual integrity + contextual integrity, defining key verified data types and violation red lines, with zero tolerance for all data irregularities.
  新版指南将数据完整性列为PAI核心核查内容，明确事实完整性+上下文完整性双重标准，划定重点核查数据类型与违规红线，所有数据问题零容忍。
  English: Core priority verification data: Finished product stability data, dissolution data, content uniformity data, API impurity test data
  优先核查核心数据：成品稳定性数据、溶出度数据、含量均匀度数据、API杂质检测数据
   Verification method: Compare primary data such as chromatograms, spectra, experimental notebooks and original logs one by one to verify consistency with CMC application summary data
  核查方式：逐一对比色谱图、光谱图、实验记录本、原始日志等一手数据，核查与CMC申报汇总数据的一致性
   Five high-risk violation scenarios (direct defect determination):
  五大高危违规情形（直接判定缺陷）：
• English: Direct falsification & replacement: Tampering with OOS unqualified data, fabricating test results, replacing new batch data with old batch data, and arbitrarily invalidating unqualified results
• 直接造假替换：篡改OOS不合格数据、编造检测结果、用旧批次数据替代新批次数据、无故作废不合格结果
• Record manipulation: Altering original records, backdating stability data, manipulating analytical procedures to avoid unqualified results, and concealing adverse data
• 记录操纵：涂改原始记录、稳定性数据倒签、操纵分析程序规避不合格结果、隐瞒不良数据
• Selective omission: Excluding defective batches, concealing abnormal test data, and failing to report key data without scientific basis
• 选择性遗漏：剔除不良批次、隐瞒异常检测数据、无科学依据不报告关键数据
• Production-record inconsistency: Inconsistent appearance of retained samples and production batches, contradictory production and equipment usage records, and unreasonable repeated testing
• 产销不符：留样与生产批次外观不一致、生产记录与设备使用记录矛盾、无合理理由重复检测
• Severe violations: Actual production process inconsistent with application materials, and unreported "shadow factory" subcontract production
• 严重违规：实际生产工艺与申报资料不符、存在未报备“影子工厂”分包生产
  Penalty consequences: Issuance of 483 forms and warning letters, product entry ban in the US market, revocation of marketing approval, full data invalidation, supply chain disruption and legal liability pursuit.
  中文：处罚后果：出具483表、下发警告信、产品拒入美国市场、撤销上市批准、数据全部作废、供应链中断、法律追责。
  
  
  6.4 Greatly Optimized Process Validation Requirements & Lowered PAI Pre-Threshold
  工艺验证要求大幅优化，放宽PAI前置门槛
  The new regulations clarify that commercial Stage 2 Process Performance Qualification (PPQ) is not mandatory before PAI, reducing enterprises’ application pressure:
  中文：新规明确不强制PAI前完成商业化Stage2工艺性能确认（PPQ），缓解企业申报压力：
• Application requirements: No need to complete full commercial process validation, but must submit a complete process validation protocol and sufficient Stage 1 process design data to prove the scientific feasibility of the process and controllable commercial production risks
• 申报要求：无需完成全部商业化工艺验证，但必须提交完整工艺验证方案，且具备充分的Stage1工艺设计数据，证明工艺科学可行、商业化生产风险可控
• Post-marketing requirements: After product approval, enterprises must complete Stage 3 continuous process confirmation to establish a long-term process stability control mechanism
• 上市后要求：产品获批后，企业必须完成Stage3持续工艺确认，建立长期工艺稳定性管控机制

7. Supervision Judgment & Penalty Mechanism: OAI Violation Red Lines
   监管判定与处罚机制：OAI违规红线
   FDA clarifies the judgment criteria for Official Action Indicated (OAI): If any one of the six core systems is out of control or has systematic CGMP defects, it will be judged as OAI non-compliant, and all API process categories of the enterprise will be uniformly deemed "unacceptable".
   FDA明确OAI（官方行动指示）判定标准：只要六大核心系统中任意一个系统失控、存在系统性CGMP缺陷，即可判定为OAI不合规，企业所有API工艺类别统一判定为“不可接受”。
   
   
   7.1 High-Frequency OAI Key Defects (Key Avoidance Points)
    高频OAI关键缺陷（重点规避）

• Existing pollution risks or actual pollution problems of APIs such as microorganisms, toxic chemicals and impurities
• API存在微生物、有毒化学品、杂质等污染风险或实际污染问题
• Systematic failure of data integrity (missing audit trails, data tampering, result falsification)
• 数据完整性系统性失效（无审计追踪、数据篡改、结果造假）
• Failure to comply with drug application commitments, inconsistent impurity profiles and process parameters with application materials
• 未遵守药品申报承诺，杂质谱、工艺参数与申报资料不一致
• Failure to evaluate and report major process and facility changes through the change management system to FDA
• 重大工艺、设施变更未通过变更管理系统评估、未报备FDA
• Unverified detection methods, untraceable reference standards and failure of laboratory control system
• 检测方法未验证、标准品无法溯源，实验室管控体系失效
  
  
  7.2 Violation Disposal for Remote Assessment
  远程评估违规处置
  Violations found in Remote Regulatory Assessment (RRA) have the same legal effect as on-site inspection defects. FDA’s Office of Manufacturing Quality (OMQ) will evaluate cases in accordance with unified procedures and trigger OAI penalties and subsequent regulatory measures.
  远程监管评估（RRA）中发现的违规问题，与现场检查缺陷同等效力，FDA OMQ将按统一流程评估，触发OAI处罚及后续监管措施。

8. Inspection Report Specifications & Document Requirements
   检查报告规范与文书要求
   English: FDA inspection documents are strictly standardized, mainly including EIR inspection reports and FDA 483 observation forms. The core requirements are as follows:
   FDA检查文书严格标准化，核心为EIR检查报告与FDA 483缺陷表，核心要求如下：

• EIR (Establishment Inspection Report): Must list verified API lists, corresponding production processes, sampling basis, and US agent information of overseas enterprises, and record all inspection findings by the six core systems to fully restore the entire verification process
• EIR检查报告：必须列明核查API清单、对应生产工艺、抽检依据、海外企业美国代理信息，按六大系统分类记录所有检查发现，完整还原核查全过程
• FDA 483 Observation Form: List defects by verification system, only based on FD&C statutory regulations (ICH Q7 is only a guiding tool, not a law enforcement basis)
• FDA 483缺陷表：按核查系统分类罗列缺陷项，仅依据FD&C法定法规，不引用ICH Q7章节（ICH Q7仅为指导工具，非执法依据）

9. Summary: Core Compliance Enlightenment for Pharmaceutical Enterprises
   总结：药企合规核心启示
   The implementation of the two major FDA new regulations in 2025-2026 marks the transformation of API supervision from ex-post inspection to full-life cycle risk control and integrated online-offline supervision. The core compliance logic is summarized as follows:
   2025-2026年FDA两大新规落地，标志着API监管从“事后核查”转向全生命周期风险管控、线上线下一体化监管，核心合规逻辑总结：
   System Priority: FDA no longer focuses on single product quality, but prioritizes the overall controlled status of enterprises’ six major systems including quality and production systems
   体系优先：FDA不再局限于单一产品质量，重点核查企业质量、生产、实验室等六大系统的整体受控状态
    Data Supremacy: Data integrity is an absolute red line; any data falsification, omission or manipulation will trigger severe penalties
   数据为王：数据完整性成为绝对红线，任何数据造假、遗漏、操纵行为均会触发严厉处罚
   Controllable Changes: The official implementation of ICH Q12 EC life cycle management makes the standardization and scientization of change management a core verification focus
   变更可控：ICH Q12 EC生命周期管理正式落地，变更管理的规范性、科学性成为核心核查重点
   Risk Adaptation: Flexible iteration of inspection modes, normalized remote verification and optimized process validation thresholds greatly improve the refinement of compliance management
   风险适配：检查模式灵活迭代，远程核查常态化、工艺验证门槛优化，合规精细化程度大幅提升
    For API pharmaceutical enterprises exporting to the US and deploying FDA applications, it is necessary to fully align with the new regulations, optimize quality systems, standardize data management, improve change management mechanisms, strengthen full-process risk prevention and control, avoid compliance risks, and ensure smooth product approval and market circulation.
   对于出口美国、布局FDA申报的API药企而言，必须全面对标新规要求，优化质量体系、规范数据管理、完善变更管控、强化全流程风险防控，规避合规风险，保障产品顺利审批与市场流通。